PortalPublikationenPrevention and management of adverse events of novel agents ...

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Standard

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. / Ludwig, Heinz; Delforge, Michel; Facon, Thierry; Einsele, Hermann; Gay, Francesca; Moreau, Philippe; Avet-Loiseau, Hervé; Boccadoro, Mario; Hajek, Roman; Mohty, Mohamad; Cavo, Michele; Dimopoulos, Meletios A; San-Miguel, Jesús F; Terpos, Evangelos; Zweegman, Sonja; Garderet, Laurent; Mateos, María-Victoria; Cook, Gordon; Leleu, Xavier; Goldschmidt, Hartmut; Jackson, Graham; Kaiser, Martin; Weisel, Katja; van de Donk, Niels W C J; Waage, Anders; Beksac, Meral; Mellqvist, Ulf H; Engelhardt, Monika; Caers, Jo; Driessen, Christoph; Bladé, Joan; Sonneveld, Pieter.

in: LEUKEMIA, Jahrgang 32, Nr. 7, 07.2018, S. 1542-1560.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Ludwig, H, Delforge, M, Facon, T, Einsele, H, Gay, F, Moreau, P, Avet-Loiseau, H, Boccadoro, M, Hajek, R, Mohty, M, Cavo, M, Dimopoulos, MA, San-Miguel, JF, Terpos, E, Zweegman, S, Garderet, L, Mateos, M-V, Cook, G, Leleu, X, Goldschmidt, H, Jackson, G, Kaiser, M, Weisel, K, van de Donk, NWCJ, Waage, A, Beksac, M, Mellqvist, UH, Engelhardt, M, Caers, J, Driessen, C, Bladé, J & Sonneveld, P 2018, 'Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network', LEUKEMIA, Jg. 32, Nr. 7, S. 1542-1560. https://doi.org/10.1038/s41375-018-0040-1

APA

Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P., Avet-Loiseau, H., Boccadoro, M., Hajek, R., Mohty, M., Cavo, M., Dimopoulos, M. A., San-Miguel, J. F., Terpos, E., Zweegman, S., Garderet, L., Mateos, M-V., Cook, G., Leleu, X., ... Sonneveld, P. (2018). Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. LEUKEMIA, 32(7), 1542-1560. https://doi.org/10.1038/s41375-018-0040-1

Vancouver

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. LEUKEMIA. 2018 Jul;32(7):1542-1560. https://doi.org/10.1038/s41375-018-0040-1

Bibtex

@article{a2d15431628d474799f38323cc191a7a,
title = "Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network",
abstract = "During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.",
keywords = "Journal Article, Review",
author = "Heinz Ludwig and Michel Delforge and Thierry Facon and Hermann Einsele and Francesca Gay and Philippe Moreau and Herv{\'e} Avet-Loiseau and Mario Boccadoro and Roman Hajek and Mohamad Mohty and Michele Cavo and Dimopoulos, {Meletios A} and San-Miguel, {Jes{\'u}s F} and Evangelos Terpos and Sonja Zweegman and Laurent Garderet and Mar{\'i}a-Victoria Mateos and Gordon Cook and Xavier Leleu and Hartmut Goldschmidt and Graham Jackson and Martin Kaiser and Katja Weisel and {van de Donk}, {Niels W C J} and Anders Waage and Meral Beksac and Mellqvist, {Ulf H} and Monika Engelhardt and Jo Caers and Christoph Driessen and Joan Blad{\'e} and Pieter Sonneveld",
year = "2018",
month = jul,
doi = "10.1038/s41375-018-0040-1",
language = "English",
volume = "32",
pages = "1542--1560",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

AU - Ludwig, Heinz

AU - Delforge, Michel

AU - Facon, Thierry

AU - Einsele, Hermann

AU - Gay, Francesca

AU - Moreau, Philippe

AU - Avet-Loiseau, Hervé

AU - Boccadoro, Mario

AU - Hajek, Roman

AU - Mohty, Mohamad

AU - Cavo, Michele

AU - Dimopoulos, Meletios A

AU - San-Miguel, Jesús F

AU - Terpos, Evangelos

AU - Zweegman, Sonja

AU - Garderet, Laurent

AU - Mateos, María-Victoria

AU - Cook, Gordon

AU - Leleu, Xavier

AU - Goldschmidt, Hartmut

AU - Jackson, Graham

AU - Kaiser, Martin

AU - Weisel, Katja

AU - van de Donk, Niels W C J

AU - Waage, Anders

AU - Beksac, Meral

AU - Mellqvist, Ulf H

AU - Engelhardt, Monika

AU - Caers, Jo

AU - Driessen, Christoph

AU - Bladé, Joan

AU - Sonneveld, Pieter

PY - 2018/7

Y1 - 2018/7

N2 - During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

AB - During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

KW - Journal Article

KW - Review

U2 - 10.1038/s41375-018-0040-1

DO - 10.1038/s41375-018-0040-1

M3 - SCORING: Review article

C2 - 29720735

VL - 32

SP - 1542

EP - 1560

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 7

ER -